Israel-based company Revamp Medical has closed a Series A preferred stock financing to support clinical trials for its Doraya catheter for the treatment of patients with heart failure.
The financing round was led by KCK Medtech, with participation from Michael Berman and existing investors Arkin and Accelmed.
KCK Medtech managing director John White said: “The Doraya catheter is a straightforward and simple-to-deploy solution for an extremely prevalent and challenging patient population.
“We are excited to partner with Revamp Medical as they continue to expand their clinical programme and validate the safety and efficacy of the Doraya catheter.”
The Doraya catheter is a temporary intravenous flow regulator and is percutaneously placed in the inferior vena cava below the level of renal veins for up to 12 hours.
It enables clinicians to manage the haemodynamics of the venous system.
The flow-reducing catheter is designed to reduce central venous pressure, renal afterload and venous return, which may reduce congestion and improve blood flow through the kidneys while enhancing the efficiency of diuretic therapy.
Revamp CEO Yael Shohat said: “We are pleased to report that our recently published first-in-human results demonstrated safety and initial evidence of improved haemodynamics, diuresis and congestion relief.”
The company is conducting the multicentre DORAYA-HF early feasibility study to evaluate the product’s practicability.
Patients are being recruited for the study which will be carried out by cardiologists at several heart failure programmes in the US.
Christ Hospital cardiology chief Dr Eugene Chung said: “The Doraya catheter represents a potential paradigm shift in the treatment of acute heart failure.”
The potential advantages of interventional decongestion include improved diuretic efficacy and urine output, decreased duration of stay in the hospital and reduced readmissions within 30 days.